Therapeutic Approach of Sodium Glucose Co-transporter Inhibitors to Reduce Mortality and Morbidity in Type 2 DM Patients with Cardio Vascular Disorders
Published: 2024-02-10
Page: 78-87
Issue: 2024 - Volume 7 [Issue 1]
Samreddy Bhavani
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
Basani Pavithra
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
Durishetty Soujanya
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
Gannoji Sainath Chary *
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
Rasuri Charishma
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
Asra Tabassum
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
M Kiranmai
St. Paul’s College of Pharmacy, Hyderabad, Telangana, India.
*Author to whom correspondence should be addressed.
Abstract
Diabetes mellitus is a metabolic syndrome, characterized by inadequate control of blood glucose levels and it is classified into Type 1, Type 2, maturity-onset diabetes of the young (MODY), gestational diabetes, neonatal diabetes, and steroid-induced diabetes. As per the epidemiological data, 537 million adults of the age between 20-79 years age-old are suffering from diabetes. Diabetic mellitus is one of the major risk factors for cardiovascular disease (CVD), people with type 2 diabetes mellitus (T2DM) have higher cardiovascular morbidity and mortality. T2DM leads to an increased risk of cardiovascular disease, with diabetes-induced micro and macrovascular complications is that major causes of morbidity and mortality in patients with T2DM. whose of 102 studies found that T2DM was associated with a 2-fold increased risk of vascular diseases such as coronary heart disease and stroke, independent of other risk factors including age, sex, smoking, body mass index, and systolic BP. The kidney’s role in the reabsorption of glucose from the glucose filtrate has led to an investigation of SGLT2 as a potential therapeutic target for T2DM. SGLT2 inhibitors decrease the capacity of the proximal tubule to reabsorb glucose from the glomerular filtrate. Clinical studies have shown that SGLT2 inhibitors improve glycemic control when employed in patients with both early and late stages of T2DM.SGLT2 inhibitors have the potential to reduce CV risk in patients with T2DM not only through beneficial effects on glycemic control, but also via beneficial effects on body weight, bp, lipids, and serum uric acid.
Keywords: SGLT2 inhibitors, antidiabetic therapy, cardio vascular complications
How to Cite
Downloads
References
Diabetes mellitus history- from ancient to modern times. (Accessed on 22nd July, 2011). Available:http://science.jrank.org/pages/2044/Diabetes-Mellitus.html
Patlak M. New weapons to combat an ancient disease: Treating diabetes. FASEB J. 2002, Dec;16(14):1853. DOI:10.1096/fj.02-0974bkt
Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281:1291–1297.
IDF Diabetes Atlas 2021 | IDF Diabetes Atlas
Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician. 2009, Jan;79(1):29-36.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham study. JAMA. 1979;241:2035–2038.
Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Journal of the American Pharmacists Association. 2009;49(Suppl 1):S10–S15.
DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes, Obesity & Metabolism. 2012;14(1):5–14.
Cefalu WT, Richards RJ, Melendez-Ramirez LY. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects. Cleveland Clinic Journal of Medicine. 2009;76:S39–S47.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364–1379.
Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. The American Journal of the Medical Sciences. 2012;343(1):21–26.
Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes — Part I: Pathways of vascular disease in diabetes. Vascular Pharmacology. 2011;54(3– 6):68–74
Cefalu WT. American diabetes association-european association for the study of diabetes position statement: Due diligence was conducted. Diabetes Care. 2012;35(6):1201–1203.
The emerging risk factors collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375: 2215–2222.
ACCORD Study group. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine. 2008; 358:2545–2559.
ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. 2008;358:2560–2572.
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376(9739): 419–430.
Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: Glucose control and cardiovascular disease in type 2 diabetes. Annals of Internal Medicine. 2009;151(6):394–403.
Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Current Cardiology Reports. 2012; 14(1):79–88.
Kabakci G, Koylan N, Ilerigelen B, Kozan O, Buyukozturk K. Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: Results from the ICEBERG study. Integrated Blood Pressure Control. 2008; 1:5–13..
Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Preventive Medicine. 2007;45(5):348–352.
Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. Lancet. 2012;380(9841):601–610.
DeSouza CV, Fonseca V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery. 2009;8(5):361–367.
Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B et al. Is the ADA/EASD algorithm for the management of type 2 diabetes(January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7): 1258–1269.
Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: Targets and newtherapies. Pharmacology and Therapeutics. 2010;125(2):328–361.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733): 2223–2233.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications. Diabetic Medicine. 2010;27(2);136–142.
Mather A, Pollock C. Glucose handling by the kidney. Kidney International. (Suppl 120), S1–S6. Musso G, GambinoR, Cassader; 2011.
Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. Journal of Internal Medicine. 2007;261(1): 32–43.
Basile J. A new approach to glucose control in type 2 diabetes: The role of kidney sodium-glucose co-transporter 2 inhibition. Postgraduate Medicine. 2011; 123(4):38–45.
Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434.
Ferrannini E, Seman LJ, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H -J. The potent and highly selective sodium glucose cotransporter-2 (SGLT-2) inhibitor BI 10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(Suppl 1):S351 [877].
Fonseca V, Ferrannini E, Wilding J, Wilpshaar W, Ball G, Klasen S. Activecontrolled dose-finding study of efficacy, safety, and tolerability of multiple doses of ipragliflozin in type 2 diabetes patients. IDF World Diabetes Congress, Dubai, UAE. 2011, December 5-9;Abstract O-0592.
Nauck MA, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care. 2011;34(9): 2015–2022.
Rosenstock J, Jelaska A, Seman L, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60:A271 [989-P].
Rosenstock J., Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6): 1232–1238.
Wilding JPH, Ferrannini E, Fonseca F, Wilpshaar W, Houzer A, de Torbal A. Efficacy and safety of ipragliflozin in type 2 diabetes patients inadequately controlled on metformin: a dose-finding study. IDF World Diabetes Congress, December 5-9, Dubai, UAE, Abstract [D-0741]; 2011.
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism. 2011;13(10):928–938.
Wilding JP,Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Annals of Internal Medicine. 2012;156(6):405–415.
Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478.
Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662.
Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes, Obesity and Metabolism. 2012; 14(6):539–545.
Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International Journal of Clinical Practice. 2012;66(5): 446–456
Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia. 2011;54(Suppl 1):S68.
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657.
Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in patients with type 2 diabetes mellitus. Diabetes Technology and Therapeutics. 2011;13(12):1219–1227
Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight. Diabetes, Obesity and Metabolism. 2010;12(6):510–516.
FDA briefing document, NDA 202293; 2011.
Available from: www.fda.gov/ downloads/ Advisory Committees / Committees Meetings Materials/drugs/Endocrinologic and Metabolic Drugs Advisory Committee/ ucm262994.pdf. Accessed 15 September 2012.
Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies. A statement of the American Diabetes Association, the north american association for the study of obesity, and the american society for clinical nutrition. American Journal of Clinical Nutrition. 2004;80:257–263.
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: A randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care. 2010;33(10):2217–2224.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733): 2223–2233.
Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends in Pharmacological Sciences. 2011;32(2):63-71.
Ferrannini E, Solini A. SGLT-2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nature Reviews Endocrinology. 2012;8(8):495–502.
Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Current Opinion in Nephrology and Hypertension. 2009;8(5):428–432.
Cefalu WT, Leiter LA, Niskanen L, Xie J, Millington D, Canovatchel W et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin. Diabetes. 2012; 61(Suppl 1A):10-LB.
Zoppini G, Targher G, Negri C, Stoico V, Perrone F, Muggeo M et al. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care. 2009;32(9):1716–1720.